Omnicell, Inc. (NASDAQ:OMCL) Given Consensus Rating of “Moderate Buy” by Analysts

Omnicell, Inc. (NASDAQ:OMCL) has been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $58.4286.

OMCL has been the subject of several recent analyst reports. Zacks Research lowered shares of Omnicell from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 10th. Weiss Ratings upgraded shares of Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, May 7th. KeyCorp reduced their price objective on shares of Omnicell from $70.00 to $65.00 and set an “overweight” rating for the company in a research report on Friday. Finally, Craig Hallum reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Omnicell in a research report on Wednesday, April 29th.

More Omnicell News

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Omnicell reported second-quarter adjusted EPS of $0.94, well above the $0.47–$0.48 consensus, while revenue rose 7.4% year over year to $312.2 million and also exceeded estimates. GAAP net income increased to $24 million from $6 million a year earlier. Omnicell Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Management raised its full-year 2026 non-GAAP EPS outlook to $2.15–$2.30, above the roughly $1.81 analyst consensus, and lifted its full-year revenue outlook to $1.225–$1.245 billion. Demand for connected devices, technical services and SaaS offerings, along with cost controls and tariff refunds, supported results. Omnicell Q2 Non-GAAP Net Income, Revenue Increase; 2026 Non-GAAP EPS Outlook Lifted
• Positive Sentiment: Omnicell highlighted momentum in its Titan XT and OmniSphere platforms, pointing to pipeline growth and longer-term opportunities in medication-management automation. KeyCorp maintained an “overweight” rating, although it reduced its price target from $70 to $65. OMCL Q2 Earnings Call Highlights Titan XT Pipeline Growth

Omnicell Price Performance

OMCL stock opened at $35.37 on Monday. The firm has a market capitalization of $1.61 billion, a PE ratio of 42.11, a P/E/G ratio of 0.92 and a beta of 0.98. The company has a quick ratio of 1.43, a current ratio of 1.64 and a debt-to-equity ratio of 0.13. Omnicell has a twelve month low of $28.90 and a twelve month high of $55.00. The stock’s 50 day moving average is $41.97 and its 200-day moving average is $41.02.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.47. The business had revenue of $312.21 million during the quarter, compared to the consensus estimate of $310.21 million. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.Omnicell’s revenue was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.45 earnings per share. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Sell-side analysts expect that Omnicell will post 1.31 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Nnamdi Njoku sold 3,090 shares of Omnicell stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $133,549.80. Following the sale, the executive vice president directly owned 154,785 shares in the company, valued at approximately $6,689,807.70. This trade represents a 1.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of the business’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total value of $217,180.50. Following the completion of the transaction, the executive vice president directly owned 112,783 shares in the company, valued at approximately $4,874,481.26. This represents a 4.27% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is owned by insiders.

Institutional Investors Weigh In On Omnicell

A number of hedge funds have recently made changes to their positions in OMCL. Dana Investment Advisors Inc. purchased a new stake in Omnicell during the fourth quarter worth about $3,445,000. Universal Beteiligungs und Servicegesellschaft mbH raised its position in Omnicell by 71.1% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 140,032 shares of the company’s stock worth $6,343,000 after acquiring an additional 58,193 shares during the period. Peregrine Capital Management LLC purchased a new position in Omnicell in the fourth quarter valued at about $4,804,000. Teachers Retirement System of The State of Kentucky boosted its stake in Omnicell by 96.3% in the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 25,914 shares of the company’s stock valued at $1,174,000 after acquiring an additional 12,713 shares during the last quarter. Finally, Jackson Creek Investment Advisors LLC bought a new position in shares of Omnicell during the 4th quarter valued at approximately $2,022,000. 97.70% of the stock is currently owned by institutional investors.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.